Susceptibility of Feline Immunodeficiency Virus/Human Immunodeficiency Virus Type 1 Reverse Transcriptase Chimeras to Non-Nucleoside RT Inhibitors

Molecular Pharmacology

Volumn 65, Issue 1, 2004, Pages 244-251

  Auwerx, Joeri ^a   Esnouf, Robert ^b   De Clercq, Erik ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; 2',3' DIDEOXYGUANOSINE TRIPHOSPHATE; [2',5' BIS O (TERT BUTYL DIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE) N3 METHYLTHYMINE; CAPRAVIRINE; CHIMERIC PROTEIN; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; FOSCARNET; MUTANT PROTEIN; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MODIFICATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; CATALYSIS; CATS; DEOXYGUANINE NUCLEOTIDES; FOSCARNET; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMIDAZOLES; IMMUNODEFICIENCY VIRUS, FELINE; KINETICS; MOLECULAR SEQUENCE DATA; NEVIRAPINE; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; SULFUR COMPOUNDS;

EID: 1642536314     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.1.244     Document Type: Article

References (29)

1. Arnold E, Jacobo-Molina A, Nanni RG, Williams RL, Lu X, Ding J, Clark AD Jr, Zhang A, Ferris AL, Clark P, et al. (1992) Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature (Lond) 357:85-89.
2. Auwerx J, North TW, Preston BD, Klarmann GJ, De Clercq E, and Balzarini J (2002) Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors. Mol Pharmacol 61:400-406.
3. Bacheler LT (1999) Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updat 2:56-67.
4. Bacolla A, Shih CK, Rose JM, Piras G, Warren TC, Grygon CA, Ingraham RH, Cousins RC, Greenwood DJ, Richman D, et al. (1993) Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem 268: 16571-16577.
5. Balzarini J, Péréz-Péréz MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ, and De Clercq E (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl] -3′-spiro-5″(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine (TSAO-T). J Biol Chem 267:11831-11838.
6. Balzarini J (1999) Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 58:1-27.
7. Bird LE, Chamberlain PP, Stewart-Jones GB, Ren J, Stuart DI, and Stammers DK (2003) Cloning, expression, purification and crystallisation of HIV-2 reverse transcriptase. Protein Expr Purif 27:12-18.
8. Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonno RJ, and Sardana VV (1992) Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 36:1441-1446.
9. D'Aquila RT and Summers WC (1989) HIV-1 reverse transcriptase/ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction. J Acquir Immune Defic Syndr 2:579-587.
10. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, and Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2:303-308.
11. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, and Stuart DI (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 94: 3984-3989.
12. Hizi A, Tal R, Shaharabany M, Currens MJ, Boyd MR, Hughes SH, and McMahon JB (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother 37:1037-1042.
13. Hsiou Y, Ding J, Das K, Clark AD Jr., Hughes SH, and Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4:853-860.
14. Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, and Arnold E (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 284:313-323.
15. Huang H, Chopra R, Verdine GL, and Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (Wash DC) 282:1669-1675.
16. Huang H, Harrison SC, and Verdine GL (2000) Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond. Chem Biol 7:355-364.
17. Isaka Y, Miki S, Kawauchi S, Suyama A, Sugimoto H, Adachi A, Miura T, Hayami M, Yoshie O, Fujiwara T, et al. (2001) A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch Virol 146:743-755.
18. Jonckheere H, De Vreese K, Debyser Z, Vandekerckhove J, Balzarini J, Desmyter J, De Clercq E, and Anné J (1996) A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. J Virol Methods 61:113-125.
19. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, and Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (Wash DC) 256:1783-1790.
20. North TW, Cronn RC, Remington KM, and Tandberg RT (1990) Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemother 34:1505-1507.
21. North TW, Hansen GL, Zhu Y, Griffin JA, and Shih CK (1994) Expression of reverse transcriptase from feline immunodeficiency virus in Escherichia coli. Antimicrob Agents Chemother 38:388-391.
22. Pelemans H, Esnouf RM, Jonckheere H, De Clercq E, and Balzarini J (1998) Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J Biol Chem 273:34234-34239.
23. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, and Stammers DK (2002) Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 99:14410-14415.
24. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, and Harrison SC (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92:1222-1226.
25. Schinazi RF, Landes BA, and Mellors JN (2000) Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antivir News 8:65-91.
26. Shih CK, Rose JM, Hansen GL, Wu JC, Bacolla A, and Griffin JA (1991) Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88:9878-9882.
27. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE, Norman M, Ren JS, Esnouf RM, Garman EF, et al. (1994) Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J Mol Biol 242:586-588.
28. Überla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Öberg B, et al. (1995) Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 92:8210-8214.
29. Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, and Prasad VR (1996) Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J Acquir Immune Defic, Syndr Hum Retrovirol 11:326-333.